iCo Therapeutics Inc  

(Public, CVE:ICO)   Watch this stock  
Find more results for cve:ico
0.0550
+0.0050 (10.00%)
Jul 11 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.05 - 0.05
52 week 0.05 - 0.59
Open 0.05
Vol / Avg. 235,000.00/1.73M
Mkt cap 4.65M
P/E     -
Div/yield     -
EPS -0.07
Shares 84.46M
Beta 0.62
Inst. own     -
May 29, 2014
Q1 2014 iCo Therapeutics Inc Earnings Release
Apr 24, 2014
Q4 2013 iCo Therapeutics Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -31.05% -163.29%
Return on average equity -46.93% -338.57%
Employees 5 -
CDP Score - -

Address

760-777 Hornby Street
VANCOUVER, BC V6Z 1S4
Canada
+1-604-6029414 (Phone)
+1-604-6029699 (Fax)

Website links

Description

iCo Therapeutics Inc. is a development stage pharmaceutical company. The Company is focused on the reprofiling and repositioning of drugs and drug candidates with a previous clinical history for new disease indications. The Company is developing iCo-007, a second generation antisense inhibitor targeting C-raf kinase messenger ribonucleic acid (mRNA), for the treatment of retinal neovascular diseases such as diabetic retinopathy (including diabetic macular edema). The iCo-008 (also known as Bertilimumab or CAT-213) is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins that acts as messenger molecules between the cells of the immune system. The Company owns the worldwide exclusive rights to an oral Amphotericin B delivery system for life-threatening infections.

Officers and directors

William W. Jarosz J.D. Independent Chairman of the Board
A. J Rae President, Chief Executive Officer, Director
W. John Meekison Chief Financial Officer, Corporate Secretary
Peter Hnik M.D. Chief Medical Officer
Age: 51
Richard W. Barker OBE Independent Director
Age: 65
Noel F. Hall Independent Director
Age: 45
Douglas G. Janzen Independent Director
Age: 41